Dr. Mittleman earned a M.D. degree from the University of Pittsburgh School of Medicine in1986, followed by residency training in Internal Medicine, fellowship training in Rheumatology, and post-doctoral training in cellular immunology. She has been at NIH since 1991, conducting both basic and clinical research. She has directed the Program on Public-Private Partnerships since it's establishment in 2005. Dr. Mittleman retains an active role in the NIAMS clinical program and an ongoing involvement in clinical research activities. Public-Private Partnerships (PPPs) represent a way for NIH to leverage it's considerable resources to work collaboratively with both public and private partners, to achieve it's mission as well as that of the partners. Partnerships may take many forms and range widely in size and scope. Partnership activities center on the shared goals and mandates of the partners, leveraging knowledge, skills, resources, and services to achieve synergy. One example is the Biomarkers Consortium. The BC is an exciting and complex PPP including several federal agencies (NIH, FDA, CMS); industry (PhRMA, BIO, and companies); academia, and patients to discover, develop, and qualify biomarkers. Better clinical care, new drugs, and enhanced regulatory decisions will result from BC

Read more: http://ppp.od.nih.gov/